Cervical Clear Cell Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: A rare morphologic variant of cervical adenocarcinoma composed of clear and hobnail cells. It is associated with in utero exposure to diethylstilbestrol (DES). 
Cervical clear cell adenocarcinomas most frequently harbor alterations in KMT2D, WWTR1, SPOP, PTEN, and PPP2R1A .
KMT2D Mutation, WWTR1 S89W, SPOP Mutation, PTEN Mutation, and PIK3CA Mutation are the most common alterations in cervical clear cell adenocarcinoma .
There are 2 clinical trials for cervical clear cell adenocarcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain cervical clear cell adenocarcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, nilotinib, and nivolumab are the most common interventions in cervical clear cell adenocarcinoma clinical trials.
Significant Genes in Cervical Clear Cell Adenocarcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for cervical clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and cervical clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.